Displaying 73 - 84 of 101
Immune-Mediated and Cholestatic Diseases
3

CymaBay Therapeutics: “Targeting New Approaches in PBC” - EASL Congress 2024

View
Immune-Mediated and Cholestatic Diseases
3

CymaBay Therapeutics: “Targeting New Approaches in PBC” - EASL Congress 2024

View
Immune-Mediated and Cholestatic Diseases
3

CymaBay Therapeutics: “Targeting New Approaches in PBC” - EASL Congress 2024

View
Immune-Mediated and Cholestatic Diseases
7

CymaBay Therapeutics: Taking Aim at Primary Biliary Cholangitis - EASL Congress 2024

View
Immune-Mediated and Cholestatic Diseases
7

CymaBay Therapeutics: Taking Aim at Primary Biliary Cholangitis - EASL Congress 2024

View
Immune-Mediated and Cholestatic Diseases
7

CymaBay Therapeutics: Taking Aim at Primary Biliary Cholangitis - EASL Congress 2024

View
Immune-Mediated and Cholestatic Diseases
7

CymaBay Therapeutics: Taking Aim at Primary Biliary Cholangitis - EASL Congress 2024

View
Immune-Mediated and Cholestatic Diseases
7

CymaBay Therapeutics: Taking Aim at Primary Biliary Cholangitis - EASL Congress 2024

View
Immune-Mediated and Cholestatic Diseases
7

CymaBay Therapeutics: Taking Aim at Primary Biliary Cholangitis - EASL Congress 2024

View
Immune-Mediated and Cholestatic Diseases
7

CymaBay Therapeutics: Taking Aim at Primary Biliary Cholangitis - EASL Congress 2024

View
Viral Hepatitis
5

Biotest: "Decoding the Best Strategies for Post-Transplant HBV Recurrence Prevention" - EASL Congress 2024

View
Viral Hepatitis
5

Biotest: "Decoding the Best Strategies for Post-Transplant HBV Recurrence Prevention" - EASL Congress 2024

View
Displaying 73 - 84 of 101